Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21755272 | 0.85 | GAA (0.47) | ALDH1A1ALOX15GAAMAPTTSHR | |
| SCHEMBL18412814 | 0.84 | ALDH1A1 (0.47) | ALDH1A1GAAMAPTTSHRSMN1; SMN2 | |
| SCHEMBL18412838 | 0.83 | MEN1 (0.44) | ALDH1A1GAAMAPTTSHRSMN1; SMN2 | |
| SCHEMBL18412837 | 0.82 | PIK3CA (0.46) | ALOX15GAATSHRSMN1; SMN2HPGD | |
| SCHEMBL31078627 | 0.81 | TSHR (0.43) | ALDH1A1ALOX15GAAMAPTTSHR | |
| SCHEMBL24611991 | 0.78 | MEN1 (0.44) | ALDH1A1GAAMAPTTSHRSMN1; SMN2 | |
| SCHEMBL27029191 | 0.78 | PRKDC (0.44) | ALDH1A1ALOX15GAAMAPTSMN1; SMN2 | |
| SCHEMBL20098347 | 0.78 | ALDH1A1 (0.45) | ALDH1A1ALOX15GAAMAPTSMN1; SMN2 | |
| SCHEMBL23226767 | 0.72 | ALDH1A1 (0.56) | ALDH1A1ALOX15MAPTSMN1; SMN2HPGD | |
| SCHEMBL25262426 | 0.72 | ALOX15 (0.50) | ALDH1A1ALOX15GAAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | ENANTA PHARM INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| EP-3687543-B1 | COMBINATIONS OF PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2024-03-20 | — | — | EP | disclosed |
| US-20230087410-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2023-03-23 | — | — | US | disclosed |
| US-20220323460-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-11390631-B1 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| WO-2019067864-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
| US-20180258102-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2018-09-13 | — | — | US | disclosed |
| EP-3324977-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170022221-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| WO-2017015449-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360155-A1 | Benzodiazepine Derivatives as RSV Inhibitors | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885ALOX15 1439/4885GAA 1755/4885 |
| US-11952389-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885ALOX15 1439/4885GAA 1755/4885 |
| US-11390631-B1 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885ALOX15 1439/4885GAA 1755/4885 |
| US-12297209-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885ALOX15 1439/4885GAA 1755/4885 |
| US-20220323460-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | ALDH1A1 3562/4885ALOX15 2880/4885GAA 305/4885 |
| US-20230087410-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885ALOX15 1439/4885GAA 1755/4885 |
| US-12268694-B2 | Combination pharmaceutical agents as RSV inhibitors | ACE, ACE2, SPCS3 | ALDH1A1 4172/4885ALOX15 3109/4885GAA 1366/4885 |
| US-20170022221-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885ALOX15 1439/4885GAA 1755/4885 |
| US-20180258102-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885ALOX15 1439/4885GAA 1755/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | ALDH1A1 3562/4885ALOX15 2880/4885GAA 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.